Altamira Therapeutics Ltd. is dedicated to developing therapeutics which addresses unmet medical needs. The Company is currently active in the development of RNA therapeutics for extrahepatic therapeutic targets, nasal sprays for protection against airborne viruses and allergens or the treatment of vertigo and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss. Altamira Therapeutics Ltd., formerly known as Auris Medical Holding Ltd., is headquartered in Hamilton, Bermuda.
Info & Links
CEO
Thomas Meyer
Headquarters
CLARENDON HOUSE, 2 CHURCH STREET HAMILTON, D0 HM 11, BERMUDA
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.